Navigation Links
Immune-boosting colorectal cancer drug shows promise
Date:7/3/2013

Lugano-Barcelona-- New data on an emerging treatment that aims to fight colorectal cancer by stimulating the immune system have been presented at the ESMO 15th World Congress on Gastrointestinal Cancer.

The findings confirm the biological action of the drug called MGN1703 and suggest it may be possible to identify which gastrointestinal cancer patients will benefit most from the treatment, reported Prof Hans-Joachim Schmoll from Martin Luther University, Halle, Germany.

MGN1703 is a small DNA molecule recognised by a receptor --called toll-like receptor 9-- that is expressed in certain immune system cells. The drug is designed to broadly activate all components of the innate immune system to stimulate the destruction of cancer cells.

The new data come from the final analysis of the phase II IMPACT study, which investigated MGN1703 in 59 patients with metastatic colorectal cancer.

The IMPACT study was an international, randomised, double-blind trial that was conducted in patients who had achieved disease control after 4.5 to 6 months of chemotherapy.

Standard chemotherapy for patients with metastatic colorectal cancer who respond to treatment is often completely or partially discontinued until the disease progresses. It was during this 'maintenance' phase of treatment that the new drug was administered.

Prof Schmoll and colleagues had intended to test the drug on 129 patients, but difficulties recruiting participants meant the trial was closed after 59 patients had been randomly assigned to either MGN1703 (43 patients) or placebo (16 patients).

"After a median follow-up of 17.3 months, MGN1703 prolonged profession-free survival from the start of induction as well as start of maintenance therapy, including four patients with sustained progression-free survival who are still on treatment," Prof Schmoll says.

A pre-planned analysis of immune cell populations showed that the activation of a particular subset of immune system cells, called Natural Killer T Cells, appeared to potentially predict which patients might benefit, Prof Schmoll said.

"We saw a significant increase of CD14+CD169+ monocytes in all but one of the MGN1703 treated patients but none of the placebo patients, which indicates the drug is having a biological effect," he said.

"These data, presented at the 15th ESMO World Congress on Gastrointestinal Cancer for the first time, are showing a highly interesting trend which should be followed-up and confirmed in a larger study," Prof Schmoll said.

Since treatment with immunotherapeutic drugs such as MGN1703 needs time to take effect, patients who have a lower tumour burden and a response to prior chemotherapy might be more likely to have a benefit of the treatment with MGN1703, Prof Schmoll said.

"The evidence we are presenting at the 15th ESMO World Congress on Gastrointestinal Cancer is the first to show an immune cell population that might also help identify patients with greater benefit from MGN1703. There is mounting evidence that patients who achieve a response with immunotherapy seem to have a very prolonged disease control. A large confirmatory trial is needed to confirm these interesting findings."

Commenting on the findings, ESMO spokesperson Michel Ducreux, Head of the Gastrointestinal Unit at the Institut Gustave Roussy, Villejuif, France, said the new results are supporting the concept for this approach.

"This is an interesting and somehow promising drug which represents a new concept of maintenance therapy with immunomodulation," he said. "The results in terms of progression-free survival and response were consistent, however based on a very small number of patients, and needs follow up and confirmation in a definitive confirmatory trial. "


'/>"/>

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Biomarker identification may lead to new noninvasive test for colorectal cancer detection
2. New gut microbiome research to explore red meat -- colorectal cancer pathway
3. Signalling pathways meeting targeting the HER/EGFR family: Focus on breast, lung and colorectal cancers
4. Study shows that diet of resistant starch helps the body resist colorectal cancer
5. 3 new genetic links to colorectal cancer
6. Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent
7. How cancer spreads: Metastatic tumor a hybrid of cancer cell and white blood cell
8. Hijacking stress response in cancer
9. Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators
10. ACRG and BGI report new evidence for the genetic bases of liver cancer
11. Cancer is a result of a default cellular safe mode, physicist proposes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... ALBANY, New York , May 4, 2016 /PRNewswire/ ... published by Transparency Market Research "Metabolomics Market - Global ... - 2024", the metabolomics market is anticipated to expand ... to reach USD 2,494.8 million by 2024. ... known as metabolites, within cells, biofluids, tissues or organisms. ...
(Date:5/3/2016)... 3, 2016 The ... Discovery, Gene Expression) Lab-on-a-chip (IVD & POC, ... Diagnostics Centers), Fabrication Technology (Microarrays, Microfluidics) - ... market is expected to reach USD 17.75 ... in 2015, growing at a CAGR of ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs from biotech, ... 31st and June 1st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... , the sensor and data driven conferences, will take place on June 7-8, 2016, at the ... UnitedHealth's Vidya Raman-Tangella on incorporating technology -- including AR/VR, machine learning, apps, robotics and ...
Breaking Biology Technology: